Bibliography
- Saito Y, Yamada N, Teramoto T, Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 2002;52(4):251-5
- Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010;11(5):817-28
- Saku K, Zhang B, Noda K, Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011;75(6):1493-505
- Ose L, Budinski D, Hounslow N, Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010;210(1):202-8
- Gumprecht J, Gosho M, Budinski D, Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20 – 40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011;13(11):1047-55
- Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther 2011;28(9):811-23
- Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther 2011;28(9):799-810
- Maruyama T, Takada M, Nishibori Y, Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-. Circ J 2011;75(8):1951-9
- Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet)-LIVALO Effectiveness and Safety (LIVES) Study-. Jpn Pharmacol Ther 2008;36:709-31
- Teramoto T, Urashima M, Shimano H, A large-scale survey on cardio-cerebrovascular events during pitavastatin (LIVALO Tablet) therapy in Japanese patients with hypercholesterolemia -LIVALO Effectiveness and Safety Study Extension (LIVES Study Extension)-. Jpn Pharmacol Ther 2011;39:789-803
- Teramoto T, Sasaki J, Ueshima H, Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14(2):45-50
- Kostapanos MS, Liamis GL, Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8(5):612-31
- Yamazaki T, Kishimoto J, Japan Prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int 2011;2(3):134-40
- Maejima T, Yamazaki H, Aoki T, Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004;324(2):835-9
- Saiki A, Murano T, Watanabe F, Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005;12(3):163-8
- Nicholls SJ, Ballantyne CM, Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365(22):2078-87